Patent EP0799896A2 successfully refreshed from Google Patents.
Patent EP0044167A2 successfully refreshed from Google Patents.
EP0044167A2
Expired / Lapsed
EP
⏱️ 0.0 years remaining
Antibody targeted cytotoxic agent
Assignee: University of California Berkeley
•
Filing: 1981-06-30
•
Granted: —
•
Expires: 2001-06-30
Abstract
Abstract Specific cytotoxic agents are provided comprising antibody specific for a surface antigen joined to a cytotoxic agent, desirably by a reductively cleavable linkage. Particularly, the cytotoxic portion of various toxins may be joined to a monoclonal antibody or fragment thereof by a disulfide linkage. The conjugate is found to be toxic for susceptible cells having the determinant site recognized by the receptor. The conjugates can be used for isolating mutant culture cells and therapeutically for destroying mutant cells present in a host.
Inventors
- 👤 Robert John Collier
- 👤 Dwight Gary Gilliland
Bibliographic Details
Application Number
—
Jurisdiction
EP
Data Source
google_patents
Last Synchronized
2026-10-23 09:22
CPC Classifications
C; C07; C07K; C07K16/00; C07K16/18; C07K16/28; C07K16/30; C07K16/3046; A; A61; A61K; A61K47/00; A61K47/50; A61K47/51; A61K47/68; A61K47/6801; A61K47/6803; A61K47/6811; A61K47/6817; A61K47/6819; A61K47/6825; A61K47/6827; A61K47/6829; A61K47/6835; A61K47/6851; A61K47/6863; A61K38/00
Claims Analysis
Total Claims: 12
Claim 1
Independent Claim
43 words
A composition consisting essentially of, as the active cytotoxic agent, a binding moiety monospecific for ,a cellular surface epitope of a susceptible cell joined to an enzymically-active fragment of a toxin by a linkage which is cleavable in the cytoplasm of susceptible cells.
Claim 2
Dependent Claim
43 words
A composition consisting essentially of, as the active cytotoxic agent, a binding moiety monospecific for ,a cellular surface epitope of a susceptible cell joined to an enzymically-active fragment of a toxin by a linkage which is cleavable in the cytoplasm of susceptible cells.
Claim 3
Dependent Claim
13 words
A composition according to claim 1, wherein said binding moiety is monoclonal antibody.
Claim 4
Dependent Claim
23 words
A composition according to claim 1, wherein ,said binding moiety is a fragment of monoclonal antibody, or a crosslinked aggregate of monoclonal antibodies.
Claim 5
Dependent Claim
16 words
A composition according to claims 1, 2 or 3, wherein said linkage involves a disulfide bridge.
Claim 6
Dependent Claim
15 words
A composition according to claim 4, wherein said fragment is a diphtheria toxin A chain.
Claim 7
Dependent Claim
15 words
A composition according to claim 4, wherein said fragment is a ricin toxin A chain.
Claim 8
Dependent Claim
48 words
A method for inhibiting multiplication of a cell having a specific surface epitope in the presence of other cells lacking said specific surface epitope, which comprises: treating the mixture of cells with a composition according to claim 1, wherein said binding moiety is specific for said surface epitope.
Claim 9
Dependent Claim
17 words
A method according to claim 7, wherein said cell having said specific epitope is a carcinoma cell.
Claim 10
Dependent Claim
47 words
A method of freeing a host of a target cell shaving a specific surface epitope which comprises: administering to said host in an amount sufficient to be cytotoxic to said cell, a composition according to claim 1, wherein said binding moiety is specific for said surface epitope.
Claim 11
Dependent Claim
13 words
A method according to claim 9, wherein said cell is a tumor cell.
Claim 12
Dependent Claim
15 words
A method according to claim 10, wherein said tumor cell is a colorectal tumor cell.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
Maintenance schedule is calculated for granted US utility patents.